Cargando…

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goshua, George, Sinha, Pranay, Kunst, Natalia, Pischel, Lauren, Lee, Alfred Ian, Cuker, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365880/ https://www.ncbi.nlm.nih.gov/pubmed/35147241 http://dx.doi.org/10.1002/ajh.26497

Ejemplares similares

Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices
por: Cuker, Adam
Publicado: (2018)

Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records
por: Lal, Lincy S., et al.
Publicado: (2020)

Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
por: Cuker, Adam, et al.
Publicado: (2023)

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
por: Cuker, Adam, et al.
Publicado: (2021)

Immune thrombocytopenia: vaccination does not equal causation
por: Pishko, Allyson, et al.
Publicado: (2022)

Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis( )
por: Pischel, Lauren, et al.
Publicado: (2022)

Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting
por: Bylsma, Lauren C., et al.
Publicado: (2018)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Heparin-induced thrombocytopenia: An illustrated review
por: May, Jori, et al.
Publicado: (2023)

Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment
por: Bussel, James B., et al.
Publicado: (2022)

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVID‐19
por: Goshua, George, et al.
Publicado: (2021)

Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia
por: Nilius, Henning, et al.
Publicado: (2021)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Falsely positive heparin‐induced thrombocytopenia antibody testing in severe hyperbilirubinemia
por: Egert, Daniel, et al.
Publicado: (2021)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients
por: Estève, Clémentine, et al.
Publicado: (2017)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
por: Butt, Ayesha, et al.
Publicado: (2023)

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
por: Lee, Eun-Ju, et al.
Publicado: (2021)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Acute on Chronic Immune Thrombocytopenia as a Cause of Thrombocytopenia in Sepsis
por: Kudaravalli, Pujitha, et al.
Publicado: (2020)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
por: Viana, Ricardo, et al.
Publicado: (2021)

First-line Therapy for Immune Thrombocytopenia: Time for Change
por: Schutgens, Roger E. G.
Publicado: (2022)

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
por: Muresan, B., et al.
Publicado: (2021)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
por: Lauren, Brianna, et al.
Publicado: (2020)

Helicobacter pylori Infection and Chronic Immune Thrombocytopenia
por: Takeuchi, Hiroaki, et al.
Publicado: (2022)

Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
por: Zhao, Shasha, et al.
Publicado: (2021)

AZD-1222/tozinameran: Immune thrombocytopenia and exacerbation of pre-existing chronic immune thrombocytopenia: 4 case reports
Publicado: (2022)

Elevated NKT cell levels in adults with severe chronic immune thrombocytopenia
por: XU, RUILONG, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hfbqkig31rcfdv515c71n37m92